BT-063 is a humanised monoclonal antibody, which selectively neutralises human interleukin-10 (IL-10).
IL-10 is involved in processes that lead to the differentiation and persistence of pathogenic B-cells in patients with SLE (Systemic Lupus Erythematosus). Neutralisation of IL-10 by BT-063 counteracts these processes and thus represents a possible new approach to the treatment of this autoimmune disease. A phase 1 clinical trial in healthy volunteers has been concluded. BT-063 is currently beeing examined in a phase IIa study in SLE patients.